Eli Lilly and Co (MIC:LLY-RM) Cyclically Adjusted PB Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (MIC:LLY-RM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.03 28.80 46.93 63.07 82.04

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.68 62.08 59.43 82.04 66.90

MIC:LLY-RM vs JNJ, ABBV, MRK: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2838.337/330.2130*330.2130
=2,838.337

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201606 846.207 241.018 1,159.368
201609 890.773 241.428 1,218.354
201612 767.792 241.432 1,050.130
201703 711.912 243.801 964.240
201706 761.015 244.955 1,025.891
201709 782.854 246.819 1,047.361
201712 606.678 246.524 812.631
201803 761.171 249.554 1,007.191
201806 676.039 251.989 885.899
201809 802.894 252.439 1,050.258
201812 646.434 251.233 849.653
201903 165.832 254.202 215.419
201906 181.510 256.143 233.998
201909 222.168 256.759 285.726
201912 168.719 256.974 216.805
202003 256.068 258.115 327.594
202006 299.428 257.797 383.538
202009 398.495 260.280 505.564
202012 439.502 260.474 557.174
202103 545.752 264.877 680.370
202106 495.193 271.696 601.846
202109 592.542 274.310 713.299
202112 696.141 278.802 824.509
202203 1,030.383 287.504 1,183.447
202206 566.512 296.311 631.329
202209 639.035 296.808 710.957
202212 685.940 296.797 763.169
202303 886.981 301.836 970.370
202306 945.897 305.109 1,023.724
202309 1,139.707 307.789 1,222.740
202312 1,080.689 306.746 1,163.365
202403 1,302.005 312.332 1,376.545
202406 1,361.598 314.175 1,431.105
202409 1,434.128 315.301 1,501.954
202412 1,710.993 315.605 1,790.188
202503 1,450.864 319.799 1,498.110
202506 1,583.694 322.561 1,621.263
202509 2,206.303 324.800 2,243.072
202512 2,357.434 324.054 2,402.240
202603 2,838.337 330.213 2,838.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.